Vistagen Therapeutics Files 8-K
Ticker: VTGN · Form: 8-K · Filed: Jun 2, 2025 · CIK: 1411685
| Field | Detail |
|---|---|
| Company | Vistagen Therapeutics, Inc. (VTGN) |
| Form Type | 8-K |
| Filed Date | Jun 2, 2025 |
| Risk Level | low |
| Sentiment | neutral |
Sentiment: neutral
Topics: 8-K, filing, regulation-fd
Related Tickers: VTGN
TL;DR
VTGN filed an 8-K on 6/2/25, check for updates.
AI Summary
On June 2, 2025, Vistagen Therapeutics, Inc. filed an 8-K report. The filing primarily concerns Regulation FD disclosures and financial statements and exhibits. No specific financial figures or material events were detailed in the provided excerpt.
Why It Matters
This filing indicates Vistagen Therapeutics is providing updates to the SEC, which could include important disclosures about the company's financial health or regulatory compliance.
Risk Assessment
Risk Level: low — The provided excerpt is a standard 8-K filing notification without specific material events or financial data that would indicate immediate risk.
Key Players & Entities
- Vistagen Therapeutics, Inc. (company) — Registrant
- 0001411685-25-000028 (document_id) — Accession Number
- June 2, 2025 (date) — Report Date
- 343 Allerton Ave. (address) — Principal Executive Offices
- South San Francisco, California (location) — Principal Executive Offices Location
FAQ
What is the primary purpose of this 8-K filing for Vistagen Therapeutics?
The filing is primarily for Regulation FD disclosures and to report financial statements and exhibits.
What is the exact date of the earliest event reported in this 8-K?
The date of the earliest event reported is June 2, 2025.
Where are Vistagen Therapeutics' principal executive offices located?
The principal executive offices are located at 343 Allerton Ave., South San Francisco, California 94080.
What is Vistagen Therapeutics' state of incorporation?
Vistagen Therapeutics, Inc. is incorporated in Nevada.
What is the SEC file number for Vistagen Therapeutics?
The SEC file number for Vistagen Therapeutics is 001-37761.
Filing Details
This Form 8-K (Form 8-K) was filed with the SEC on June 2, 2025 regarding Vistagen Therapeutics, Inc. (VTGN).